{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:44Z","timestamp":1772119544603,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10552-024-01912-1","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T08:02:12Z","timestamp":1725955332000},"page":"1557-1563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2988-7544","authenticated-orcid":false,"given":"Gilberto","family":"Barranco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itzel","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dulce","family":"Gama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zazueta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma","family":"Olarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iveth","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Arcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"issue":"9","key":"1912_CR1","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H (2022) Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol [Internet]. 97(9):1236\u201356. https:\/\/doi.org\/10.1002\/ajh.26642","journal-title":"Am J Hematol [Internet]."},{"issue":"4","key":"1912_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3816\/clk.2008.n.036","volume":"2","author":"A Aguayo","year":"2008","unstructured":"Aguayo A, Garcia-Alvarez E, Cazares-Ordonez Y, Crespo-Solis E, Martinez-Ba\u00f1os D, Guadarrama-Beltran E et al (2008) Chronic myeloid leukemia: a clinicoepidemiologic and therapeutic description of a single institution in Mexico city. Clin Leuk [Internet]. 2(4):261\u20136. https:\/\/doi.org\/10.3816\/clk.2008.n.036","journal-title":"Clin Leuk [Internet]."},{"issue":"11","key":"1912_CR3","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1182\/blood.v110.11.4557.4557","volume":"110","author":"A Aguayo","year":"2007","unstructured":"Aguayo A, Garcia-Alvarez E, Cazares-Ordonez Y, Crespo-Solis E, Martinez-Banos D, Elizabeth G-BSW et al (2007) Chronic myeloid leukemia. 15-years experience at a single Institution in Mexico city. Blood [Internet]. 110(11):4557\u20134557. https:\/\/doi.org\/10.1182\/blood.v110.11.4557.4557","journal-title":"Blood [Internet]."},{"issue":"6","key":"1912_CR4","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1002\/cam4.2201","volume":"8","author":"J Ylescas-Soria","year":"2019","unstructured":"Ylescas-Soria J, de la Torre-Lujan AH, Herrera LA, Miranda D, Grimaldo F, Rivas S et al (2019) Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute - Mexico, from 2000 to 2016. Cancer Med [Internet]. 8(6):2942\u20139. https:\/\/doi.org\/10.1002\/cam4.2201","journal-title":"Cancer Med [Internet]."},{"issue":"4","key":"1912_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/ejh.12743","volume":"97","author":"N Gunnarsson","year":"2016","unstructured":"Gunnarsson N, Sandin F, H\u00f6glund M, Stenke L, Bj\u00f6rkholm M, Lambe M et al (2016) Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. Eur J Haematol [Internet]. 97(4):387\u201392. https:\/\/doi.org\/10.1111\/ejh.12743","journal-title":"Eur J Haematol [Internet]."},{"issue":"1","key":"1912_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1186\/s12885-018-4984-3","volume":"18","author":"E Di Felice","year":"2018","unstructured":"Di Felice E, Roncaglia F, Venturelli F, Mangone L, Luminari S, Cirilli C et al (2018) The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study. BMC Cancer [Internet]. 18(1):1069. https:\/\/doi.org\/10.1186\/s12885-018-4984-3","journal-title":"BMC Cancer [Internet]."},{"issue":"9","key":"1912_CR7","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/10428194.2022.2068000","volume":"63","author":"E Szczepanek","year":"2022","unstructured":"Szczepanek E, Chukwu O, Kami\u0144ska M, Wysogl\u0105d H, Cenda A, Zawada M et al (2022) Long-term outcomes of patients with chronic myeloid leukemia who commenced treatment with imatinib: a 20-year single-centre experience. Leuk Lymphoma [Internet]. 63(9):2213\u201323. https:\/\/doi.org\/10.1080\/10428194.2022.2068000","journal-title":"Leuk Lymphoma [Internet]."},{"issue":"2","key":"1912_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41375-019-0699-y","volume":"34","author":"T Radivoyevitch","year":"2020","unstructured":"Radivoyevitch T, Weaver D, Hobbs B, Maciejewski JP, Hehlmann R, Jiang Q et al (2020) Do persons with chronic myeloid leukaemia have normal or near normal survival? Leukemia [Internet]. 34(2):333\u20135. https:\/\/doi.org\/10.1038\/s41375-019-0699-y","journal-title":"Leukemia [Internet]."},{"issue":"2","key":"1912_CR9","first-page":"1","volume":"22","author":"M\u00c1 Gonz\u00e1lez Block","year":"2020","unstructured":"Gonz\u00e1lez Block M\u00c1, Reyes Morales H, Hurtado LC, Balandr\u00e1n A, M\u00e9ndez E (2020) Mexico: health system review. Health Syst Transit [Internet]. 22(2):1\u2013222","journal-title":"Health Syst Transit [Internet]."},{"key":"1912_CR10","doi-asserted-by":"publisher","first-page":"100277","DOI":"10.1016\/j.eclinm.2020.100277","volume":"19","author":"M Breccia","year":"2020","unstructured":"Breccia M (2020) Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: a therapeutic goal has been reached. EClin Med [Internet]. 19:100277. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100277","journal-title":"EClin Med [Internet]."},{"issue":"1","key":"1912_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1744-8603-5-19","volume":"5","author":"P Kanavos","year":"2009","unstructured":"Kanavos P, Vandoros S, Garcia-Gonzalez P (2009) Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP. Global Health [Internet]. 5(1):19. https:\/\/doi.org\/10.1186\/1744-8603-5-19","journal-title":"Global Health [Internet]."},{"issue":"4","key":"1912_CR12","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia [Internet]. 34(4):966\u201384","journal-title":"Leukemia [Internet]."},{"issue":"S2","key":"1912_CR13","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","volume":"2","author":"M H\u00f6glund","year":"2015","unstructured":"H\u00f6glund M, Sandin F, Simonsson B (2015) Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol [Internet]. 2(S2):S241-7. https:\/\/doi.org\/10.1007\/s00277-015-2314-2","journal-title":"Ann Hematol [Internet]."},{"issue":"3","key":"1912_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3322\/caac.21772","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A (2023) Colorectal cancer statistics, 2023. CA Cancer J Clin [Internet]. 73(3):233\u201354. https:\/\/doi.org\/10.3322\/caac.21772","journal-title":"CA Cancer J Clin [Internet]."},{"issue":"2","key":"1912_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.clml.2015.10.006","volume":"16","author":"M Ayala","year":"2016","unstructured":"Ayala M, \u00c1vila E, Dom\u00ednguez J, Aquino X, Vela J (2016) Diagnosis and treatment of chronic myeloid leukemia in the imatinib mesylate era: report of the experience at \u201cLa Raza\u201d medical center in Mexico. Clin Lymphoma Myeloma Leuk [Internet]. 16(2):57\u201362. https:\/\/doi.org\/10.1016\/j.clml.2015.10.006","journal-title":"Clin Lymphoma Myeloma Leuk [Internet]."},{"issue":"2","key":"1912_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/ejh.12695","volume":"97","author":"N Thielen","year":"2016","unstructured":"Thielen N, Visser O, Ossenkoppele G, Janssen J (2016) Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012. Eur J Haematol [Internet]. 97(2):145\u201354. https:\/\/doi.org\/10.1111\/ejh.12695","journal-title":"Eur J Haematol [Internet]."},{"key":"1912_CR17","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.eclinm.2020.100257","volume":"19","author":"CA Umeh","year":"2020","unstructured":"Umeh CA, Garcia-Gonzalez P, Tremblay D, Laing R (2020) The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: the glivec international patient assistance program (GIPAP). EClinicalMedicine [Internet]. 19:100257. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100257","journal-title":"EClinicalMedicine [Internet]."}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-024-01912-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-024-01912-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-024-01912-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T07:33:52Z","timestamp":1731569632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-024-01912-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1912"],"URL":"https:\/\/doi.org\/10.1007\/s10552-024-01912-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2779417\/v1","asserted-by":"object"}]},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Hospital General de M\u00e9xico Dr. Eduardo Liceaga and Instituto Nacional de Cancerologia, a research ethics committee, approved the study, which was performed per the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}